Wolfgang Miesbach/LinkedIn
Feb 20, 2026, 17:35
Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“At EAHAD 2026 it became very clear that, in haemophilia B, plasma FIX is only part of the story.
Great presentation by Cedric Hermans.
- FIX ≠ FVIII
FVIII is mainly intravascular, while FIX distributes both intra‑ and extravascularly, binding to collagen IV and endothelium and forming a kind of tissue ‘reservoir’. This dual compartment may help explain why some patients do better clinically than their plasma levels would suggest. - EHL‑FIX: more than just longer half‑life
The three extended half‑life FIX products use different technologies (Fc‑fusion, albumin‑fusion, PEGylation), leading to distinct volumes of distribution, extravascular engagement and joint localisation on imaging. These differences translate into variable trough levels and bleed protection across phase 3 studies, suggesting that EHL‑FIX products are not interchangeable simply on dose interval. - Extravascular FIX as ‘savings account’
I liked the analogy of intravascular FIX as “daily expenses” and extravascular FIX as “savings”: what we measure in plasma is immediately available, but the tissue‑bound pool may provide crucial back‑up at bleeding sites, as supported by several preclinical models.
This raises interesting questions for the future:
- How should we factor extravascular FIX into target levels and PK‑guided prophylaxis?
- What does this mean for choosing between different EHL‑FIX platforms and for interpreting FIX levels after gene therapy?”

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants